603939 益丰药房
2023/09 - 九个月
人民幣(K¥)
与去年同期
比较
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
2019/12
人民幣(K¥)
营业总收入15,888,04719.03%19,886,39615,326,30513,144,50210,276,175
减:营业总成本14,471,70019.13%18,008,27514,045,64112,062,1119,485,875
    其中:营业成本9,604,56721.82%12,025,5649,142,8188,152,0716,267,593
               财务费用63,008-24.76%104,812114,870141,52238,475
               资产减值损失(53,459)36.11%(56,019)(40,746)(31,404)(16,130)
公允价值变动收益------------
投资收益36,247394.66%6,86934,36829,42011,178
    其中:对联营企业和合营企业的投资收益(2)-85.95%(11)--2,1681,754
营业利润1,468,81720.65%1,885,5331,338,8671,133,484815,468
利润总额1,467,80420.34%1,877,4871,337,9061,127,365814,296
减:所得税费用339,53511.99%450,292347,157287,923205,412
净利润1,128,26923.10%1,427,195990,749839,443608,884
减:非控股权益129,08538.91%161,585102,86495,92065,134
股东净利润999,18421.32%1,265,610887,884743,523543,750

市场价值指针
每股收益 (元) *0.99020.73%1.7601.2501.0801.031
每股派息 (元) *----0.4000.3000.3000.300
每股净资产 (元) *9.294-17.30%11.85510.4099.88311.898
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容